$4.15
+0.10 (+2.47%)
Open$4.13
Previous Close$4.05
Day High$4.17
Day Low$4.05
52W High$6.95
52W Low$3.27
Volume—
Avg Volume157.4K
Market Cap243.66M
P/E Ratio—
EPS$-1.17
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+598.6% upside
Current
$4.15
$4.15
Target
$28.99
$28.99
$18.54
$28.99 avg
$38.99
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 29.53M | 25.21M | 271.86M |
| Net Income | -70,963,024 | -54,521,701 | 13.33M |
| Profit Margin | -240.3% | -228.3% | 4.9% |
| EBITDA | -79,343,820 | -64,347,472 | 20.13M |
| Free Cash Flow | — | — | 11.27M |
| Rev Growth | +17.1% | +17.1% | -6.6% |
| Debt/Equity | — | — | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |